Document Detail

Long-term intravenous administration of activated autologous lymphocytes for cancer patients does not induce antinuclear antibody and rheumatoid factor.
MedLine Citation:
PMID:  15330194     Owner:  NLM     Status:  MEDLINE    
The treatment of activated autologous lymphocyte can lead to a potent antitumor effect with destruction of autologous cancer cells, but potential adverse autoimmune effects due to destruction of autologous tissue must also be considered. This study was performed to evaluate whether administration of activated autologous lymphocytes induces autoimmune disease. Patients with advanced cancer, who underwent transfer therapy with activated autologous lymphocytes, were eligible for the study. Informed consent was obtained from 22 patients with hepatocelluler carcinoma, ovarian cancer, gastric cancer, etc. The variation in activated lymphocyte phenotypes was CD3+/HLA-DR+ activated T lymphocytes, 23% to 99%; including CD4+ cells, 4% to 65%; CD8+ cells, 10 to 91%; and CD16+/ICD56+ NK cells, 1% to 59%. Of the 22 patients, levels of antinuclear antibody and/or rheumatoid factor were above normal limits during the study in the following 5 patients: 3 patients showed no marked changes, one patient a slight decrease in rheumatoid factor and one patient a slight increase in antinuclear antibody during the course of treatment, respectively. The values for these markers of the other 17 patients varied within normal limits during treatment. Mild transient fever occurred in several patients as an adverse event. There were no other adverse reactions. No clinical symptoms or signs suggestive of autoimmune disease occurred in any patient during or after treatment. These results suggested that long-term administration of activated autologous lymphocytes does not induce autoimmune disease.
Tomohiro Yamaguchi; Kenzo Bamba; Ayari Kitayama; Yasuyuki Kuroiwa; Kazuhiko Yoshimatsu; Takeshi Shimakawa; Kenji Ogawa; Teruaki Sekine; Norio Shimizu; Kohtaro Yamamoto
Related Documents :
1182684 - Thymosin-induced increase in e-rosette-forming capacity of lymphocytes in patients with...
19877054 - Clinical and histologic evidence of salivary gland restoration supports the efficacy of...
18606984 - Survival patterns among lymphoma patients with a family history of lymphoma.
8562414 - Blood clonal b-cell excess in patients with monoclonal gammopathy of undetermined signi...
2311114 - Cerebrospinal fluid shunt malfunction signaled by new or recurrent seizures.
11228184 - Strict volume control normalizes hypertension in peritoneal dialysis patients.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  24     ISSN:  0250-7005     ISO Abbreviation:  Anticancer Res.     Publication Date:    2004 Jul-Aug
Date Detail:
Created Date:  2004-08-27     Completed Date:  2004-09-23     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  2423-9     Citation Subset:  IM    
Lymphotec Inc., Bunkyo-ku, Tokyo 112-0001, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Antinuclear / biosynthesis*,  blood,  immunology
Antigens, CD3 / immunology
Autoimmune Diseases / blood,  etiology*,  immunology
Immunotherapy, Adoptive / adverse effects*,  methods
Lymphocytes / immunology*
Middle Aged
Neoplasms / blood,  immunology*,  therapy*
Rheumatoid Factor / biosynthesis*,  blood,  immunology
Reg. No./Substance:
0/Antibodies, Antinuclear; 0/Antigens, CD3; 9009-79-4/Rheumatoid Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Radiofrequency ablation combined with percutaneous ethanol injection in the treatment of hepatocellu...
Next Document:  Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population.